Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia

Key facts

Sponsor

Juventas Cell Therapy Ltd.

Principal Investigator

Jianxiang Wang, Dr.

Institute of Hematology & Blood Diseases Hospital, China

Intervention

single dose of CNCT19(biological)

Enrollment

100 enrolled

Eligibility

18-65 years · All sexes

Timeline

2020 – 2026

Study locations (11)

• Beijing Boren Hospital, Beijing, Beijing Municipality, China
• Xinqiao Hospital of TMMU, Chongqing, Chongqing Municipality, China
• Nanfang Hospital, Guangzhou, Guangdong, China
• Yanda hospital, Hebei medical university, Sanhe, Hebei, China
• Henan Cancer Hospital, Zhengzhou, Henan, China
• Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
• The affiliated hospital of Xuzhou medical university, Xuzhou, Jiangsu, China
• Tongji Hospital of Tongji University, Shanghai, Shanghai Municipality, China
• West China Hospital，Sichuan University, Chengdu, Sichuan, China
• Institute of Hematology & Blood Diseases Hospital, Tianjin, Tianjin Municipality, China
• The First Affiliated Hospital, Zhejiang University school of Medicine, Hangzhou, Zhejiang, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Acute lymphoblastic leukemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT05621291
  A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT07328503
  CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
  National Cancer Institute (NCI)
• RECRUITINGPHASE2NCT06738368
  Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia
  University of Washington
• ENROLLING BY INVITATIONNCT07511959
  Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative Dentistry
  Wroclaw Medical University
• RECRUITINGNANCT07191119
  Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic Leukemia
  St. Jude Children's Research Hospital
• RECRUITINGNANCT07177183
  Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning Failure
  University Hospital Ostrava
• RECRUITINGPHASE2NCT07275762
  Y-4 to Treat the Postherpetic Neuralgia
  Neurodawn Pharmaceutical Co., Ltd.
• RECRUITINGNANCT07201974
  Virtual Reality for Post-Stroke Gait Rehabilitation
  McGill University

See all trials for Acute lymphoblastic leukemia →